Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatmentKoji Haratani, Kazuhiko Nakagawa, Yasutaka Chiba et al.|Annals of Oncology|2017Cited by 294
B7-H3 Negatively Modulates CTL-Mediated Cancer ImmunityKimio Yonesaka, Kazuhiko Nakagawa, Koji Haratani et al.|Clinical Cancer Research|2018Cited by 169
Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid TumorsMasayuki Takeda, Kazuto Nishio, Takayuki Takahama et al.|The Oncologist|2020Cited by 95
Detection of the T790M mutation of <i>EGFR</i> in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)Takayuki Takahama, Kazuto Nishio|Oncotarget|2016Cited by 72